8Bala MV,Mauskopf JA,Wood LL.Willingness to pay as a measure of health benefits. Pharmacoeconomics . 1999
9Olsen JA,Smith RD.Theory versus practice:a review of‘willingness-to-pay’in health and health care. Journal of Health Economics . 2001
10Marra CA,Frighetto L,Goodfellow AF,Wail AO,Chase ML,Nicol RE,Leong CA,Tomlinson S,Ferreira BM,Jewesson PJ.Willingness to pay to assess patient preferences for therapy in a Canadian setting. BMC Health Services Research . 2005
7Einarson,TR,Granton,J T,Vicente,C,et al.Cost-effectiveness of treprostinil Versus epoprostenol in patients with pulmonary arterial hypertension:a Canadian analysis[J].Can Respir J,2005.12(8):419-425.
8Saha,L.,Pandhi,P,Gopalan,S,et al.Comparison of efficacy.tolerability,and cost of iron polymaltose complex with ferrous sulphate in the treatment of iron deficiency anemia in pregnant women[J].Med Gen Med,2007,9(1):1.
9National Institute For Clinical Excellence.Health T Technology Appraisals Process Series:Guidance for Manufacturers and Sponsors.London:National Institute For Clinical Excellence,2001:11.
10Attard C L.Maroun J A,Alloul K,et al,Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada[J].Curt Oncol,2010,17(1):17-24.
